Author + information
- Spencer B. King III, MD, MACC, Editor-in-Chief, JACC: Cardiovascular Interventions⁎ ()
- ↵⁎Address correspondence to:
Spencer B. King III, MD, MACC, Editor-in-Chief, JACC: Cardiovascular Interventions, Saint Joseph's Heart and Vascular Institute, 5665 Peachtree Dunwoody Road, NE, Atlanta, Georgia 30342
This is the 36th issue of JACC: Cardiovascular Interventions and, as such, it has reached a degree of maturity as a resource for investigators to publish their important research findings and for practitioners of cardiovascular medicine to keep abreast of these advances in the field. This was my response when I was asked for my “elevator speech” describing what the journal is about. If the elevator ride were 1 floor more, I would add that it is truly an international journal. (Elevator or lift? We do get many papers from the United Kingdom.) The international contributions to the success of the journal were brought to my attention even more acutely at the recent EuroPCR meeting in Paris.
EuroPCR, as I indicated in this column last year, is a very large and highly organized international symposium that again was extremely successful in its educational goals. It differs mainly in form from the American College of Cardiology (ACC) and Transcatheter Cardiovascular Therapeutics (TCT) symposia, since industry-sponsored educational sessions are still possible outside of the United States. I would add that their sessions were without any industry control, and I detected no bias in presentations. Of course, the subject matter was of interest to the sponsoring industry. The debate about industry involvement in education is an important one but not for this limited space.
For us (the journal), there were 2 highlights at the EuroPCR. First, we were invited to participate in a joint JACC: Cardiovascular Interventions/EuroInterventions symposium on publishing. I chaired this session with Patrick Serruys, and the presentations on preparing papers, statistical methods, impact factor, reviewing papers, and the future of publishing were well received by an overflow audience. This is the kind of collaboration that I think is helpful for authors, reviewers, and editors alike to improve medical publishing. I hope similar sessions will be held at the major cardiovascular conferences.
We also took advantage of the venue in Paris to hold an editorial board meeting, and we invited board members and frequent authors to provide input for improvement of the journal. We were joined by Anthony DeMaria, Editor-in-Chief of JACC, and a lively discussion ensued. Board meetings are traditionally combined JACC, JACC: Cardiovascular Interventions, and JACC: Cardiovascular Imaging, but this meeting was more intimate and focused on interventions. Perhaps we will repeat these types of gatherings at future interventional conferences. The meeting gave us a chance to present the state of the journal statistics to a group of major contributors to the journal who were attending EuroPCR. We presented them the following facts about the journal. The circulation is now greater than 11,000, which is a 17% increase from last year. Submissions continue to rise: 441 (2008), 663 (2009), 737 (2010), and now 300 in the first four months of 2011. The largest number of submissions in 2010 came from the United States (39%), but the next 10 leading contributors were Italy, Japan, the Netherlands, Canada, Germany, United Kingdom, Spain, France, Korea, and India and Israel tied. In 2010, publications were: 122 new research, 36 editorial comments, 12 state-of-the-art papers, and 18 Images in Intervention. Focused issue subjects since inception have included the following topics: platelet responsiveness, stent technology, stent strut coverage, systems of care for acute myocardial infarction, transradial approach, second-generation drug-eluting stents, chronic total occlusion, percutaneous coronary intervention for unprotected left main disease, transcatheter aortic valve implantation (TAVI), long-term outcomes for drug-eluting stents, outcomes for ST-segment elevation myocardial infarction, and new directions for platelet inhibition. Contributors to the journal include: 1,265 authors, 603 reviewers, and 100 editorial comment authors. In addition, there are 40 online interviews of authors conducted by the editors. At the meeting in Paris, we discussed where the journal is going, especially in the near future for online publishing and the app for JACC: Cardiovascular Interventions and JACC: Cardiovascular Imaging on the iPad. Some very high quality congenital heart disease and peripheral vascular disease papers are in press. As we look forward to the release of the impact factor for the journal at the end of June, we anticipate even more interest and must prepare to cope with our page limitations. The current acceptance rate for research papers is only 16%, and in order to be able to publish the quality papers submitted, more pages might be necessary. Several positive suggestions came from those attending the board meeting and reception, and we welcome suggestions from readers as well.
One other activity for the journal was an exhibit sponsored by the ACC and TCT highlighting the collaboration of the 2 organizations in the fall (TCT venue) and spring (ACC venue) major interventional meetings in the United States. Finally, a prominent feature of the EuroPCR was the continuing experience and investigation of TAVI. Note that in this issue, there are several papers on TAVI that were the subject of significant discussion at the meeting in Paris. All of you who have contributed to the growth and maturity of this journal should be proud.
- American College of Cardiology Foundation